NPUK has been informed by Sanofi of supply interruptions affecting Xenpozyme (olipudase alfa), a treatment for Acid Sphingomyelinase Deficiency (ASMD).
As of November 2026, Sanofi anticipates a shortage of olipudase alfa in some countries. Sanofi has also advised that, based on current supply forecasts and anticipated consumption, global supply of olipudase alfa is expected to become insufficient to meet global demand beginning in mid-2027.
We recognise that this news may cause concern and uncertainty for people living with ASMD and their families, particularly those who rely on regular treatment.
Sanofi has advised that it is working to manage global supply and minimise the impact on people living with ASMD. The company is also working to increase long-term production capacity and develop potential approaches intended to help preserve access to treatment for as many people as possible.
What should people currently receiving Xenpozyme do?
If you or a family member are receiving Xenpozyme and have questions or concerns about your treatment, please contact your treating physician or specialist clinical team for individual advice.
What is NPUK doing?
NPUK is engaging with Sanofi, specialist clinicians, the International Niemann-Pick Disease Alliance (INPDA) and the wider Niemann-Pick community to understand the situation and its potential impact on people living with ASMD.
We are committed to advocating for the needs of people living with ASMD and their families, supporting access to clear and accurate information, and helping to ensure that the experiences and concerns of our community are heard.
We are also considering how best to understand the experiences of people living with ASMD who may be affected by supply interruptions. Further information may be shared with the community as this work develops.
Further information:
For further information and updates regarding the Xenpozyme supply situation, please refer to information provided directly by Sanofi:
https://www.sanofi.com/en/our-science/therapeutic-areas/rare-diseases/supply-update
NPUK will continue to monitor the situation and share relevant information with the UK Niemann-Pick community as it becomes available.
10
Nov